Hsbc Holdings PLC Acquires 37,433 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Hsbc Holdings PLC increased its stake in Nkarta, Inc. (NASDAQ:NKTX) by 102.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,845 shares of the company’s stock after acquiring an additional 37,433 shares during the period. Hsbc Holdings PLC owned approximately 0.10% of Nkarta worth $171,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in NKTX. Invesco Ltd. purchased a new position in shares of Nkarta in the 4th quarter worth approximately $30,000. Sequoia Financial Advisors LLC purchased a new stake in Nkarta during the 4th quarter valued at $31,000. China Universal Asset Management Co. Ltd. bought a new stake in Nkarta in the fourth quarter worth $37,000. Catalina Capital Group LLC boosted its stake in Nkarta by 57.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock worth $47,000 after buying an additional 6,867 shares during the period. Finally, Sei Investments Co. purchased a new position in Nkarta during the fourth quarter worth $57,000. 80.54% of the stock is owned by institutional investors.

Nkarta Price Performance

Shares of NKTX opened at $1.95 on Monday. The firm has a market capitalization of $138.01 million, a price-to-earnings ratio of -1.03 and a beta of 0.81. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.23. The company has a 50-day moving average of $1.78 and a 200 day moving average of $2.24.

Nkarta (NASDAQ:NKTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, equities analysts anticipate that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NKTX. Stifel Nicolaus reduced their target price on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 27th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Nkarta in a research report on Wednesday, April 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Nkarta in a research note on Thursday, March 27th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Nkarta currently has an average rating of “Buy” and an average target price of $14.83.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.